The study, by a team led by University of Bristol researchers, in a clinical trial investigated whether the treatment called Glial Cell Line Derived Neurotrophic Factor (GDNF) - a natural protein, found in the brain - can regenerate dying dopamine brain cells in patients with Parkinson's and reverse their condition, something no existing treatment can do. The results potentially demonstrated that the new treatment was starting to reawaken and restore damaged brain cells and that repeated brain infusion is clinically feasible and tolerable, according in the Journal of Parkinson's Disease.
The study "represents some of the most compelling evidence yet that we may have a means to possibly reawaken and restore the dopamine brain cells that are gradually destroyed in Parkinson's", said principal investigator from the University of Bristol in the UK. After an initial safety study of six…
